Esketamine Combined With Magnesium Sulfate for Postoperative Fatigue Syndrome in Patients Undergoing Laparoscopic Cholecystectomy

NCT ID: NCT07131033

Last Updated: 2025-08-19

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 120 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-05-06
• Study Completion Date: 2025-09-30

Brief Summary

Laparoscopic cholecystectomy (LC), while minimally invasive, triggers postoperative fatigue syndrome (POFS) through mechanisms including ischemia-reperfusion injury, neuroendocrine stress (sustained cortisol elevation), and inflammation-driven mitochondrial dysfunction (IDO-mediated kynurenine production). Esketamine, an NMDA receptor antagonist, counteracts POFS by blocking central sensitization, suppressing neuroinflammation (e.g., microglial IL-6 release), and enhancing neuroplasticity via BDNF/TrkB upregulation. Magnesium sulfate complements this by antagonizing NMDA/voltage-gated calcium channels to reduce inflammation and calcium overload, while optimizing cellular energy metabolism as an ATPase cofactor and alleviating muscle spasms. Crucially, their combination holds synergistic potential: esketamine targets central fatigue pathways, while magnesium addresses peripheral metabolic and muscular components. This study aims to determine their individual and interactive effects on POFS, recovery quality, and sleep outcomes in LC patients, establishing an efficient, safe strategy to accelerate postoperative rehabilitation.

Detailed Description

This randomized, double-blind trial investigated the effects of esketamine and magnesium sulfate on postoperative fatigue syndrome in patients undergoing laparoscopic cholecystectomy. Using computer-generated randomization and sealed envelopes, 120 patients were allocated in a 1:1:1:1 ratio to four groups: Group E received intravenous esketamine (0.25 mg/kg over 10 min pre-induction followed by 0.25 mg/kg/h); Group M received magnesium sulfate (30 mg/kg over 10 min pre-induction followed by 10 mg/kg/h); Group EM received both drugs concurrently at the specified doses; and Group C received volume-matched normal saline. Patients, attending anesthesiologists, and outcome assessors remained blinded to group assignment throughout the study, with intraoperative management handled by a separate non-investigating anesthesiologist to preserve blinding integrity.

The patients were routinely fasted for 6 h and abstained from drinking for 2 h preoperatively. All patients were not anesthetized with premedication. After admission, patients were routinely administered oxygen by mask, peripheral venous access was opened and cardiac monitoring, including noninvasive blood pressure, pulse oximetry, electrocardiogram, body temperature and entropy index, was routinely performed. Both groups were routinely rapidly induced with midazolam 0.05 mg/kg, propofol 1.5 mg/kg, rocuronium bromide 1mg/kg, and sufentanil 0.5 μg/kgrespectively. Preoxygenation was administered for 3 min followed by endotracheal intubation and connection to a ventilator with 50％ oxygen of 2.0 L/min for respiratory control. Setting parameters: tidal volume 6～8 ml/kg, inspiratory ratio 1:2, control PETCO2 at 35～40 mmHg. During anaesthesia maintenance, remifentanil 0.1-0.5 ug/kg/min, sevoflurane (1%-3%) and propofol 4-12 mg/kg/h were continuously infused in all three groups.Sevoflurane (1%-3%), and Propofol 4-12 mg/kg/h were continuously infused in all three groups.A four-channel microinfusion pump was used for synchronous intravenous infusion. Each drug was administered through an independent channel to avoid drug interactions, and the drugs were continuously infused during the operation until the end of the surgery. The appropriate depth of anesthesia (entropy index RE/SE 40-60) was maintained by adjusting the infusion rate of propofol and remifentanil. At the appropriate depth of anaesthesia, vasoactive drugs (ephedrine, phenylephrine, nitroglycerin) can be administered to regulate blood pressure.After the operation, the patient was immediately transferred to the PACU. when the patient regained consciousness and could breathe on his own, the tracheal tube was removed. In the PACU, 30 mg of ketorolac tromethamine was administered intravenously to relieve analgesia if the patient's NRS score was >3 or if the patient required analgesia.

Conditions

Laparoscopic Cholecystectomy; Alleviate Postoperative Fatigue Syndrome

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Esketamine

Patients were given intravenous esketamine 0.25 mg/kg 10 min before induction of anaesthesia, followed by continuous pumping at 0.25 mg/(kg-h) until the end of the operation.

Group Type: EXPERIMENTAL

Esketamine

Intervention Type: DRUG

Patients were given intravenous esketamine 0.25 mg/kg 10 min before induction of anaesthesia, followed by continuous pumping at 0.25 mg/(kg-h) until the end of the operation.

Magnesium Sulfate

Patients were injected with 30 mg/kg of magnesium sulphate intravenously 10 min before the induction of anaesthesia, followed by continuous pumping at 10 mg/(kg-h) until the end of the operation.

Group Type: EXPERIMENTAL

Magnesium sulfate

Intervention Type: DRUG

Patients were injected with 30 mg/kg of magnesium sulphate intravenously 10 min before the induction of anaesthesia, followed by continuous pumping at 10 mg/(kg-h) until the end of the operation.

Esketamine and Magnesium Sulfate

Patients received a simultaneous intravenous infusion of esketamine (0.25 mg/kg) and magnesium sulfate (30 mg/kg) over 10 minutes before anesthesia induction, followed by continuous infusion of esketamine at 0.25 mg/kg/h and magnesium sulfate at 10 mg/kg/h via separate channels until surgery completion.

Group Type: EXPERIMENTAL

Esketamine and Magnesium sulfate

Intervention Type: DRUG

Patients received a simultaneous intravenous infusion of esketamine (0.25 mg/kg) and magnesium sulfate (30 mg/kg) over 10 minutes before anesthesia induction, followed by continuous infusion of esketamine at 0.25 mg/kg/h and magnesium sulfate at 10 mg/kg/h via separate channels until surgery completion.

Control

Patients in the control group received an equivalent volume of normal saline infused intravenously over 10 minutes before anesthesia induction, followed by continuous saline infusion at a matched flow rate via a separate channel until surgery completion.

Group Type: PLACEBO_COMPARATOR

Saline

Intervention Type: DRUG

Patients in the control group received an equivalent volume of normal saline infused intravenously over 10 minutes before anesthesia induction, followed by continuous saline infusion at a matched flow rate via a separate channel until surgery completion.

Interventions

Esketamine

Patients were given intravenous esketamine 0.25 mg/kg 10 min before induction of anaesthesia, followed by continuous pumping at 0.25 mg/(kg-h) until the end of the operation.

Intervention Type: DRUG

Magnesium sulfate

Patients were injected with 30 mg/kg of magnesium sulphate intravenously 10 min before the induction of anaesthesia, followed by continuous pumping at 10 mg/(kg-h) until the end of the operation.

Intervention Type: DRUG

Esketamine and Magnesium sulfate

Patients received a simultaneous intravenous infusion of esketamine (0.25 mg/kg) and magnesium sulfate (30 mg/kg) over 10 minutes before anesthesia induction, followed by continuous infusion of esketamine at 0.25 mg/kg/h and magnesium sulfate at 10 mg/kg/h via separate channels until surgery completion.

Intervention Type: DRUG

Saline

Patients in the control group received an equivalent volume of normal saline infused intravenously over 10 minutes before anesthesia induction, followed by continuous saline infusion at a matched flow rate via a separate channel until surgery completion.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Age between 18 and 65 years
• American Society of Anesthesiologists (ASA) classification I-II
• Patients scheduled for LC under general anaesthesia and with a procedure duration of less than 60 minutes.

Exclusion Criteria

• Patients who do not sign the informed consent;
• patients with severe diseases of major organs such as the heart, brain, lungs, liver, and kidneys;
• patients with adverse drug reactions to esketamine or magnesium sulfate;
• patients with uncontrolled hypertension or hyperthyroidism;
• patients with endocrine and metabolic diseases or neurological diseases;
• pregnant or lactating women;
• long-term users of sedatives, analgesics, or long-term alcohol abusers;
• patients with a history of mental illness, language communication barriers, or inability to understand the content of the experiment;
• patients with difficult airways during anesthesia induction requiring a change in the conventional intubation method;
• patients with sinus bradycardia or atrioventricular block;
• patients with concurrent cholangitis, biliary obstruction, or pancreatitis.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

The Second People's Hospital of Huai'an

OTHER

Sponsor Role: lead

Responsible Party

Chenglan Xie

chief physician

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

The Affiliated Huaian Hospital of Xuzhou Medical University, Huai'an Second Hospital

Huaian, , China

Countries

China

References

Lacourt TE, Vichaya EG, Chiu GS, Dantzer R, Heijnen CJ. The High Costs of Low-Grade Inflammation: Persistent Fatigue as a Consequence of Reduced Cellular-Energy Availability and Non-adaptive Energy Expenditure. Front Behav Neurosci. 2018 Apr 26;12:78. doi: 10.3389/fnbeh.2018.00078. eCollection 2018.

Reference Type: BACKGROUND

PMID: 29755330 (View on PubMed)

Zargar-Shoshtari K, Hill AG. Postoperative fatigue: a review. World J Surg. 2009 Apr;33(4):738-45. doi: 10.1007/s00268-008-9906-0.

Reference Type: BACKGROUND

PMID: 19189174 (View on PubMed)

Zhuang CL, Mao XY, Liu S, Chen WZ, Huang DD, Zhang CJ, Chen BC, Shen X, Yu Z. Ginsenoside Rb1 improves postoperative fatigue syndrome by reducing skeletal muscle oxidative stress through activation of the PI3K/Akt/Nrf2 pathway in aged rats. Eur J Pharmacol. 2014 Oct 5;740:480-7. doi: 10.1016/j.ejphar.2014.06.040. Epub 2014 Jun 27.

Reference Type: BACKGROUND

PMID: 24975098 (View on PubMed)

Chen W, Liu S, Chen F, Zhou C, Zhuang C, Shao S, Yu J, Huang D, Chen B, Yu Z. [Relationship between NMDA receptor and postoperative fatigue syndrome and its associated central mechanism]. Zhonghua Wei Chang Wai Ke Za Zhi. 2015 Apr;18(4):376-81. Chinese.

Reference Type: BACKGROUND

PMID: 25940183 (View on PubMed)

Wang X, Lin C, Lan L, Liu J. Perioperative intravenous S-ketamine for acute postoperative pain in adults: A systematic review and meta-analysis. J Clin Anesth. 2021 Feb;68:110071. doi: 10.1016/j.jclinane.2020.110071. Epub 2020 Oct 26.

Reference Type: BACKGROUND

PMID: 33007645 (View on PubMed)

Lin X, Feng X, Sun L, Wang Y, Wu X, Lu S, Shao L, Wang W, Yang L, Geng W, Lin H. Effects of esketamine on postoperative fatigue syndrome in patients after laparoscopic resection of gastric carcinoma: a randomized controlled trial. BMC Anesthesiol. 2024 May 24;24(1):185. doi: 10.1186/s12871-024-02513-w.

Reference Type: BACKGROUND

PMID: 38789968 (View on PubMed)

Sun L, Zhao Y, Li Y, Zhai W, Gao F, Yin Q, Cheng W, Wang Z, Zeng Y. Effect of continuous subanesthetic esketamine infusion on postoperative fatigue in patients undergoing laparoscopic radical resection for colorectal cancer: a randomized controlled study. Am J Cancer Res. 2023 Jun 15;13(6):2554-2563. eCollection 2023.

Reference Type: BACKGROUND

PMID: 37424809 (View on PubMed)

De Oliveira GS Jr, Castro-Alves LJ, Khan JH, McCarthy RJ. Perioperative systemic magnesium to minimize postoperative pain: a meta-analysis of randomized controlled trials. Anesthesiology. 2013 Jul;119(1):178-90. doi: 10.1097/ALN.0b013e318297630d.

Reference Type: BACKGROUND

PMID: 23669270 (View on PubMed)

Fritzen R, Davies A, Veenhuizen M, Campbell M, Pitt SJ, Ajjan RA, Stewart AJ. Magnesium Deficiency and Cardiometabolic Disease. Nutrients. 2023 May 17;15(10):2355. doi: 10.3390/nu15102355.

Reference Type: BACKGROUND

PMID: 37242238 (View on PubMed)

Other Identifiers

CLanXie

Identifier Type: -

Identifier Source: org_study_id